

1 Reply to Harada

2

3 **Author names and affiliations**

4 Takumi Kagawa, MMSc^{a,b}

5 Akira Tazaki, PhD^{a,b}

6 Huadong Xu, MPH^{a,b}

7 Nobutaka Ohgami, PhD^{a,b}

8 Masashi Kato MD, PhD^{a,b}

9

10 From ^athe Department of Occupational and Environmental Health, Nagoya University
11 Graduate School of Medicine, Nagoya, Japan and ^bVoluntary Body for International
12 Healthcare in Universities, Nagoya, Japan

13

14 **Corresponding author**

15 Masashi Kato MD, PhD

16 Department of Occupational and Environmental Health, Nagoya University Graduate
17 School of Medicine, Nagoya, Japan

18 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan

19 Phone: 052-744-2124

20 Fax: 052-744-2126

21 E-mail: katomasa@med.nagoya-u.ac.jp

22

23 **Disclosure of potential conflict of interest:**

24 T. Kagawa has received scholarship from the Convolution of Informatics and
25 Biomedical Sciences on Glocal Alliances (CIBoG) from the Ministry of Education,
26 Culture, Sports, Science and Technology. A. Tazaki has received grants from the
27 Ministry of Education, Culture, Sports, Science and Technology. H. Xu has received
28 scholarship from the China Scholarship Council. N. Ohgami has received grants from
29 the Ministry of Education, Culture, Sports, Science and Technology. M. Kato has
30 received grants from the Ministry of Education, Culture, Sports, Science and
31 Technology., the Japan Science and Technology Agency, the Kobayashi International
32 Scholarship Foundation and the AEON Environmental Foundation.

33

34 **Funding statement:**

35 This study was supported in part by Grants-in-Aid for Scientific Research (A)
36 (15H01743, 15H02588 and 19H01147), (B) (17KT0033 and 20H03929), (C)
37 (16K08343) and Challenging Exploratory Research (20K21708) from Ministry of
38 Education, Culture, Sports, Science and Technology; Mirai-Program Small Start Type
39 from the Japan Science and Technology Agency; Kobayashi International Scholarship
40 Foundation and AEON Environmental Foundation.

41

42 **Key Words:** Air pollutant; intranasal exposure; lead; Japanese cedar pollen; seasonal
43 allergic rhinitis

44 **Reply to Harada**

45

46 *To the Editor:*

47 We thank Nanayakkara et al.¹ for the comments on and interest in our article.

48 We in this reply focus on 1) diameter of air particles that affects pollinosis, 2) lead

49 levels of the purchased cedar pollens collected from the tree before dispersion in

50 Table E4 and 3) pathological modification of nasal mucosa in subjects with allergic

51 rhinitis (Fig. E5).

52 Air particles of $\leq 2.5 \mu\text{m}$ in diameter ($\text{PM}_{2.5}$) can reach the lower airway through

53 the upper airway, while those of $>10 \mu\text{m}$ in diameter including cedar pollen particles

54 of about $40 \mu\text{m}$ in diameter¹ are trapped in the upper airway. We disagree with the

55 calculation of intranasal lead level by Nanayakkara et al. without considering the

56 sizes of air particles that pass through the nasal cavity.¹ In this reply, we first consider

57 a source of intranasal lead with focus on air particles of $>10 \mu\text{m}$ in diameter that can

58 be trapped in the nasal cavity.

59 There is a positive correlation between lead level in nasal epithelial lining fluid

60 (ELF) and dispersed pollen counts (TABLE II), indicating that increased lead level in

61 ELF is partially dependent on dispersed pollens. However, the source of intranasal

62 lead in ELF remains unknown. Lead level of air particles of $>10 \mu\text{m}$ in diameter

63 account for only $<2\%$ of the total lead concentration in all air particles,² indicating that

64 $>98\%$ of lead in air particles can pass through the nasal cavity. Furthermore, pollens

65 can adhere to air particles of $\leq 10 \mu\text{m}$ in diameter (SPMs) including heavy metals

66 during dispersion.³ These results indicate that increased lead level of pollen through

67 dispersion as well as the limited lead level of large air particles that are trapped in the

68 nasal cavity should be considered for estimation of the contribution of lead in air

69 particles to the lead level in ELF.

70 Nanayakkara et al. estimated the intranasal lead level by purchased pollens
71 before dispersion (Table E4).¹ Following their method of calculation, we propose
72 another hypothesis considering the increased lead level of pollen through
73 dispersion.¹ Weights of SPMs of 10 μm in diameter and standard density are
74 approximately 5.2×10^{-10} g. One gram of SPMs contains 850×10^3 ng/g lead.⁴ If a
75 pollen adheres to 3 SPMs through dispersion, the lead level in the pollen could be
76 estimated as 0.17 ng/m^3 [$125 \text{ (grain/m}^3) \times 5.2 \times 10^{-10} \text{ (g/particle)} \times 3 \text{ (particle)} \times 850 \times$
77 $10^3 \text{ (ng·Pb/g·SPM)}$].⁴ The maximum concentration of air particles of $>10 \mu\text{m}$ in
78 diameter could be 0.4 ng/m^3 [$20 \text{ ng/m}^3 \times 2/100 \text{ (2\%)}$]. The maximum lead level per
79 day that is accumulated in the nasal cavity of allergic patients is estimated to be 12.3
80 ng [$(0.17 \text{ ng/m}^3 + 0.4 \text{ ng/m}^3) \times 21.6 \text{ m}^3 \text{ (air volume of respiration per day)}$]. The
81 estimated level is roughly comparable to the increased lead level in ELF from pre-
82 season to season in allergic patients (Fig. 1A). Thus, SPMs containing a higher lead
83 level, which intrinsically pass through the nasal cavity, may come to be trapped in the
84 nasal cavity by adhesion of SPMs to pollens during dispersion. This is our suggested
85 mechanism of the increased intranasal level of Pb partially derived from pollen.
86 Further study on the lead level of dispersed pollens is needed to more strictly
87 elucidate the origin of intranasal lead.

88 Nanayakkara et al. considered intranasal lead level based on the volume of
89 nasal mucosal mucus and nasal mucociliary clearance time in healthy subjects.¹
90 Although the review of pathologic factors of allergic subjects as well as environmental
91 factors are important for our allergotoxicologic analysis, they overlook the
92 pathological differences including the volume of nasal mucosal mucus and nasal
93 mucociliary clearance time between non-allergic healthy subjects and allergic
94 subjects. Moreover, our results in model mice indicate 7-fold and 4.7-fold increased

95 goblet cell number and mucins in nasal mucosa, respectively, in allergic mice treated
96 with an antigen and lead compared to those in non-allergic mice with no treatment
97 (FIG E5). Lead has been reported to be accumulated in goblet cells and mucins in
98 the small intestine.⁵ These results suggest that the pathological modification induced
99 by co-exposure to an antigen and lead in nasal mucosa of allergic subjects further
100 increases the intranasal lead level in allergic subjects.

101 Our model mice with allergic rhinitis were treated with liquid lead nitrate but not
102 air particles including lead. A different method for exposure to lead may differently
103 affect the accumulated level of intranasal lead. However, lead concentration in
104 murine ELF (13.7 $\mu\text{g}/\text{mL}$) was comparable to that in human ELF (27.2 $\mu\text{g}/\text{mL}$). These
105 results suggest that the treated lead dose is physiologically acceptable to observe
106 the effects of lead on the pathogenesis of allergic rhinitis.

107 Finally, we appreciate the comments by Nanayakkara et al. on lead
108 concentrations in urine samples.¹ Due to our error in calculation, lead concentrations
109 in urine samples were expressed as 100-fold higher than the correct values in Fig.1C
110 and Table E1. An attached erratum to our article has been sent for rectification.

111

112 *Takumi Kagawa, MMSc^{a,b}*

113 *Akira Tazaki, PhD^{a,b}*

114 *Huadong Xu, MPH^{a,b}*

115 *Nobutaka Ohgami, PhD^{a,b}*

116 *Masashi Kato MD, PhD^{a,b}*

117

118 From ^athe Department of Occupational and Environmental Health, Nagoya University
119 Graduate School of Medicine, Nagoya, Japan and ^bVoluntary Body for International

120 Healthcare in Universities, Nagoya, Japan.

121

122 **REFERENCES**

123 1. Nanayakkara S, Yamamoto N, Harada K. Intranasal level of lead estimated from
124 airborne pollen and urinary lead levels in Japan. *J Allergy Clin Immunol* 2021; in
125 press.

126 2. Allen AG, Nemitz E, Shi JP, Harrison RM, Greenwood JC. Size distribution of trace
127 metals in atmospheric aerosols in the United Kingdom. *Atmospheric Environment*
128 2001;35:4581-4591.

129 3. Visez N, Ivanovsky A, Roose A, Gosselin S, Sénéchal H, Poncet P, Choël M.
130 Atmospheric particulate matter adhesion onto pollen: a review. *Aerobiologia*
131 2020;36:49-62.

132 4. Khan MF, Hirano K, Masunaga S. Quantifying the source of hazardous elements of
133 suspended particulate matter aerosol collected in Yokohama, Japan. *Atmospheric*
134 *Environment* 2010;44:2646-2657.

135 5. Tomczok J, Grzybek H, Sliwa W, Panz B. Ultrastructural aspects of the small
136 intestinal lead toxicology. *Exp. Pathol* 1988;35:93-100.